Dynamic leader and Senior Scientist from Cardinal Health, Inc., with over 20 years of expertise in US and Global CMC Regulatory Affairs and Project Management. Excelled in driving strategic FDA submissions and global compliance, leveraging strong project management and scientific writing skills. Proven track record in fostering cross-functional partnerships and enhancing scientific outcomes through innovative solutions.
Sklice (ivermectin, 0.5% lotion) Pre-clinical through Phase 3 Diclectin (doxylamine succinate 10mg/Pyridoxine HCl 10mg) FTIH through Phase 2 Zorvolex (nano-particle diclofenac) Phase 2 to Phase 3 Tivorbex (nano-particle indomethacin) Phase 2 to Phase 3 INL-001 (bupivacaine-collagen implant) Phase 2 INL-002 (gentamicin topical) Phase 2 Factor X (BLA) Tecovirimat (ST-246, smallpox) pre-clinical to Phase 3 PZ-601 (carbapenem) Phase 2 DIFICID (fidaxomicin) Pre-clinical to NDA